About this trial
Research Background:
Pediatric acute liver failure (PALF) refers to the sudden onset of severe liver injury in children without known chronic liver disease, leading to multi-system organ dysfunction, with a mortality rate as high as 50%-70%. The etiology of PALF is complex and varied, including infections, metabolic disorders, and toxins. In developed countries, it is often caused by drug and toxin exposure, while in developing countries, viral infections are the primary cause. Additionally, 30%-50% of PALF cases have an unknown etiology, which increases the difficulty of treatment. Current treatment options include medical management, artificial liver support, and liver transplantation. Liver transplantation is the only proven effective treatment, but issues such as organ shortages and the timing of transplantation affect treatment outcomes. Improving diagnostic capabilities for the etiology and exploring optimal treatment strategies are of significant importance in enhancing the clinical success rate of PALF management.
Research Objective:
To explore the etiology and prognostic factors of pediatric acute liver failure (PALF), analyze the relationship between different causes of PALF and prognosis, and the relationship between different treatment modalities and prognosis. This study aims to investigate the correlation between etiology, treatment methods, and outcomes, providing scientific evidence to improve the precision in diagnosis and treatment of PALF and to enhance decision-making and timing judgments for liver transplantation.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
For patients who were admitted twice, only the information from the first hospitalization will be used.
Patients with a history of chronic liver disease (e.g., genetic metabolic factors, drug-induced factors) or biliary obstruction that led to the acute episode are categorized under acute liver failure.
The child's legal guardian has signed a written informed consent form.
Disqualifiers
Age > 18 years;
Significant data missing (>10%);
The child's legal guardian refuses participation.
Trial population
Criteria for Diagnosing Pediatric Acute Liver Failure
Trial design
Cohort
Other
Treatments tested in this trial
Not listed
Trial groups
Trial outcomes
Primary outcomes
Discharge Status
Cured: * Clinical symptoms such as bleeding tendency and hepatic encephalopathy disappear; * Jaundice resolves (TBil ≤ 2× upper limit of normal); ③ Liver function markers return to baseline; ④ PTA/INR normalizes. Improved: ① Significant improvement in clinical symptoms like bleeding, and disappearance of hepatic encephalopathy; * Significant improvement in jaundice, ascites, and other physical signs; ③ Liver function markers show marked improvement (TBIL \< 5× upper limit of normal, PTA \> 40% or INR \< 1.5). Worsened: No improvement in symptoms or signs of liver failure, liver function deteriorates, and complications increase or worsen. Death or death within one week after withdrawal of treatment. Liver Transplantation.
Locations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
liyumei
Lead sponsor
The First Hospital of Jilin University
Sponsor institution
This trial is not recruiting at the moment. You can still explore other options: